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 Abstract 
 Recent advances in ischemic stroke enable a seamless transition of the patient flow from the 
prehospital setting to definitive reperfusion, without the arbitrary separation of therapeutic 
phases of ischemia based on time alone. In 2013, the framework to understand and directly 
address the pathophysiology of cerebral blood flow that determines the timeline or evolution 
of ischemia in an individual case is given. This continuum of flow and the homeostasis of brain 
perfusion balanced by collaterals may be captured with serial imaging. Ongoing imaging core 
laboratory activities permit large-scale measurement of angiographic and tissue biomarkers 
of ischemia. Prehospital neuroprotection has become a reality and may be combined with 
revascularization therapies. Recent studies confirm that image-guided thrombolysis may be 
achieved without restrictive time windows. Baseline imaging patterns may be used to predict 
response to therapy and serial imaging may discern recanalization and reperfusion. Advanced 
techniques, such as arterial spin-labeled MRI, may also report hyperperfusion associated with 
hemorrhagic transformation. Endovascular therapies, including novel stent retriever devices, 
may augment revascularization and angiographic core laboratories may define optimal reper-
fusion. Serial evaluation of collaterals and reperfusion may identify definitive reperfusion 
linked with good clinical outcome rather than imposing arbitrary definitions of effective re-
canalization. Reperfusion injury and hemorrhagic transformation of various types may be de-
tailed to explain clinical outcomes. Similar approaches may be used in intracranial atheroscle-
rosis where flow, and not the degree of luminal stenosis, is paramount. Fractional flow may 
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now be measured with computational fluid dynamics to identify high-risk lesions that require 
revascularization to restore the equilibrium of antegrade and collateral perfusion. Serial per-
fusion imaging of such cases may also illustrate inadequate cerebral blood volume gradients 
that may be more informative than blood flow delay alone. In sum, the growing understand-
ing of collateral perfusion throughout all stages of ischemic stroke provides a framework for 
the future of ischemic stroke.  © 2014 S. Karger AG, Basel 
 Introduction 
 The field of ischemic stroke has been transformed in 2013, as the framework to study 
cerebral blood flow has been established. Stroke care providers now appreciate that cerebral 
ischemia is undoubtedly a dynamic process. In this context, there is no need to designate arbi-
trary separation of different phases of ischemia as hyperacute, acute or subacute. The exact 
time points are difficult to demarcate, as are the justifications for such time boundaries. There 
may be general time epochs, but the proper way to understand time is along a continuum of 
changing blood flow states that evolve over prolonged time periods in any individual. Each 
patient manifests its own trajectory in terms of survival from ischemia  [1] .
 Imaging data at more than one time point for any individual patient, irrespective of the 
modality of the study, may be illuminating regarding the underlying pathophysiology. Such 
serial imaging not only illustrates how much ischemic injury has evolved, but it is also 
important to evaluate the effects of attempted therapeutic interventions, to appreciate the 
impact of a given therapy and to measure the degree of reperfusion, if any. The infrastructure 
and technology to assess all these factors through various modalities including serial CT, MRI 
and angiography are now available.
 Against this backdrop, we have witnessed the development of numerous new interven-
tional devices  [2–4] to manage acute ischemic stroke. However, defining optimal medical 
therapy for large artery disease has been challenging. Paradoxically, the ultimate conse-
quence of hypoperfusion, or ischemia, has been largely overlooked and remains untargeted 
other than via restoration of upstream arterial patency.
 Time Is NOT Brain! 
 Reconsideration of cerebral ischemia as a dynamic and evolving process, unfolding over 
time, rather than arbitrarily split into artificial time windows, provides insight on the over-
simplified notion that time is brain. Although it is true that across populations of stroke 
cohorts, it is possible to calculate averages for the amount of brain tissue lost or burden of 
ischemic injury based on different time phases, the course of an individual patient cannot 
be predicted. Population statistics can yield a specific estimate of cellular injury in the brain, 
yet one must remember that such an average does not predict the course of an individual 
patient  [1] .
 Time is routinely used to mark the onset of neurological symptoms, yet the time of 
symptom onset is almost never equivalent to the time of vascular occlusion. What is regarded 
as the time from symptom onset directly reflects time from collateral failure, when collaterals 
can no longer offset or sustain blood flow affected by upstream arterial occlusion  [1] . Even 
with sites of arterial occlusion that may be associated with devastating outcomes, such as 
middle cerebral artery or internal carotid artery occlusions, other individuals may be 
completely asymptomatic or solely harbor silent ischemic lesions. This distinction among 
cases depends completely on the degree of collateral circulation ( fig. 1 ).
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 Imaging Perspective on Time 
 Defining different time phases for an individual patient is not easy. If a patient presents 
with already jeopardized cerebral blood flow and there is a malignant pattern evidenced on 
initial imaging, even within 1 h of symptom onset, such a case should no longer be considered 
‘acute’ as there are no therapeutic opportunities. So how should we define ‘acute’?
 If there is an opportunity to evaluate a patient with imaging at two time points and 
measure the time-to-imaging in a series of patients and put it in a graph of brain tissue loss 
versus time, each individual patient will have a different curve or time course of ischemic 
injury. Likewise, serial imaging in stroke patients, who are managed conservatively, may 
demonstrate that each patient is slightly different as they have their own disease course. With 
the aid of imaging, those patients who need early and aggressive intervention may be iden-
tified earlier.
 Flow Determines Time 
 The amount of collateral flow and its capacity to compensate for hypoperfusion governs 
time; it determines the time from vascular occlusion to the onset of symptom, the nature of 
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 Fig. 1. Schematic illustration of the relation between time and brain tissue loss, noting marked dissimilarity 
between  a pathophysiology measured from time from vascular occlusion (TFVO) and  b measures utilizing 
time from symptom onset (TFSO). Each individual curve represents unique temporal features of a particular 
case, including baseline brain volume, time to symptom onset or collateral failure, degree of collateral depen-
dence influenced by lesion location, and resultant infarct volume. Rapid decompensation caused by poor col-
laterals in abrupt cardioembolic occlusion ( a , 1) may lead to large infarcts at very early time points, whereas 
progressive ischemia and robust collateralization in intracranial atherosclerosis ( a , 2) may manifest with a 
long time window and smaller infarct volumes. In the absence of imaging, time alone measured from symp-
tom onset ( b , circle) is often used to group these identical curves and calculate brain lost based on a linear, 
rather than a biologically plausible sigmoid model. 
108Intervent Neurol 2013;2:105–117
 DOI: 10.1159/000357164 
 Ip and Liebeskind: The Future of Ischemic Stroke: Flow from Prehospital 
Neuroprotection to Definitive Reperfusion  
www.karger.com/ine
© 2014 S. Karger AG, Basel
symptoms (e.g. fluctuating or stuttering course) and it also determines when intervention 
may be necessary.
 The significance of cerebral blood flow may not merely define such time points; hemody-
namics may actually predict possible outcomes of reperfusion. For instance, a partial middle 
cerebral artery stroke evolves and leads to infarction in a fractional area of that territory. As 
time progresses, that area will have increased resistance because of poor inflow and asso-
ciated venous collapse  [1] . As flow is diminished, even if treatment is instituted rapidly, reper-
fusion may yield an unsatisfactory result or negligible clinical impact. From this perspective, 
we may realize that addressing time alone may not be sufficient for achieving definitive reper-
fusion and good clinical outcome.
 Continuum and Homeostasis of Flow 
 A balance exists between proximal arterial compromise and the corresponding collateral 
flow. For instance, leptomeningeal anastomoses provide collateral flow to adjacent cerebral 
and cerebellar arterial territories. Diversion of flow through these diminutive structures 
allows for retrograde perfusion of the collapsed arterial bed distal to the occlusion ( fig. 2 )  [5] .
 Shunting at the circle of Willis may be relatively simple in terms of local flow diversion, 
yet the vast network of leptomeningeal collaterals is quite complex and knowledge remains 
limited on their function. Leptomeningeal collateral flow is driven by hemodynamic factors 
such as the pressure gradient between adjacent arterial territories  [5, 6] . As retrograde or 
reverse collateral flow into the occluded arterial territory is driven by the sudden pressure 
drop downstream from an occlusion, the resultant increased flow through these small anas-
tomoses causes an increase in fluid shear stress (FSS) and a complex chain of events that 
likely involves release of various cytokines, triggering vascular remodeling  [1] . Another 
mechanism that could contribute to vascular remodeling is hypertension, in which angio-
tensin II appears to be a critical mediator  [7] . Such cerebral arteriogenesis promotes outward 
growth of anastomoses and eventual accommodation for impairment of flow with normal-
ization of FSS.
 Fig. 2. Diagram of leptomeningeal collaterals, bridging the anterior and middle cerebral arteries (a), the pos-
terior and middle cerebral arteries (b), the superior and posterior cerebral arteries (c), and the major cere-
bellar hemispheric arteries (d).  
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 Today, advanced technology enables us to use serial imaging to differentiate time curves 
of an individual patient, discerning collateral recruitment and subsequent fluctuations. 
Spatial coregistration of serial CT or MRI datasets permits evaluation of serial changes in 
blood flow with either CT or MRI perfusion in a particular area of brain or voxel. Such 
approaches can also relate what happens in terms of voxel-based changes for impact of flow 
on ischemic infarction or hemorrhagic transformation as shown on FLAIR or T2-weigheted 
sequences  [8] . As a result, we can predict from one volume of interest of voxel at baseline to 
other time points, the relationship between changes in blood flow and tissue fate in that 
particular region, ranging from infarction to hemorrhage or neither.
 Imaging Infrastructure 
 The infrastructure to study the evolution of cerebral ischemia is now available. Many 
clinicians routinely acquire serial imaging at baseline, after intervention and even during 
later phases of hospitalization  [1] . Although such imaging may not be acquired for a particu-
lar research study and simply for clinical indications, such data are extremely valuable for 
understanding the pathophysiology of stroke.
 In stroke trials, imaging has principally been used in secondary roles with respect to 
outcomes. Imaging addresses exploratory or ancillary aims, yet never eclipses the principal 
objective of evaluating therapeutic impact of a novel intervention on clinical outcomes. 
Clinical outcome is always the ultimate priority and imaging features are typically subsidiary 
to whether novel therapy works or not.
 Ideally, prospective imaging data are desired, but retrospective analyses of such imaging 
data are also useful. It is now feasible to implement large-scale imaging analyses via core labo-
ratory activities and worldwide collaborations.
 The decision about acquisition or even collection of routine imaging is limited by funding, 
as the question of resources always arises. Unfortunately, the focus of every trial is typically 
about therapeutic intervention and consideration of imaging is frequently discounted. Various 
funding sponsors, including industrial or governmental, place a different amount of interest 
on imaging but it is always secondary to determining the clinical impact of a novel therapy. 
Nonetheless, imaging insurance at the start of a trial may reveal influential pathophysiology 
even at later phases of clinical trials. Lessons from imaging in phase 2 trials may characterize 
key mechanisms to target in subsequent phase 3 clinical trials. Quite frequently, however, 
only limited imaging is obtained to confirm key pathophysiology and subsequent studies 
often proceed without imaging. Even after a phase 3 clinical trial, the imaging data are dis-
regarded if the trial has been negative, without careful consideration of pivotal determi-
nants  [1] . 
 Neuroprotection 
 The year 2013 marks an important milestone in the history of neuroprotective agents for 
stroke with the completion of the first prehospital neuroprotection stroke study, the Field 
Administration of Stroke Therapy-Magnesium (FAST-MAG) trial  [9] . It is time to think about 
the relationship between neuroprotection and cerebral blood flow, and how these relate to 
such early drug administration.
 FAST-MAG Trial 
 The FAST-MAG trial aims to demonstrate that paramedic initiated intravenous infusion 
of magnesium sulfate within 2 h of symptom onset improves long-term functional outcome 
of stroke patients  [10] . The trial was implemented using a voice-over-internet protocol simul-
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taneous ring system to enable physician-investigators to obtain consent immediately from 
competent patients or legally authorized representatives. The trial completed the 1,700th 
final patient recruitment in December 2012, and preliminary observation of the first 1,470 
patients revealed a median interval time of 46 min from symptom onset to drug adminis-
tration, with 73% of subjects receiving the study drug within 1 h of symptom onset  [10] .
 It is important to consider the initiation of neuroprotection during these early phases as 
it allows the use of neuroprotectives to freeze or preserve the penumbra without altering the 
vascular status. The next steps will incorporate neuroprotection with revascularization, and 
this may provide a platform to synergize neuroprotection with blood flow restoration.
 Thrombolysis 
 While everyone attempts to extend the time window of thrombolysis, it is recognized that 
the baseline imaging can actually predict response. Revascularization entails recanalization 
(i.e. opening up an artery) and reperfusion which signifies reestablishing flow in the down-
stream territory. It is now possible to look at the effects of thrombolysis on both recanali-
zation and reperfusion with serial use of multimodal CT/MRI. Hyperperfusion and the impact 
of sudden changes in blood flow may also be studied with respect to sequelae such as hemor-
rhage.
 Early and Late – Does Time Matter? 
 Recent studies provided some interesting findings related to the role of time duration in 
cerebral ischemia and the impact of thrombolysis. In a German study, thrombolysis was given 
in a mobile stroke unit with the overall purpose of initiating revascularization as early as 
possible to potentially improve associated neurological outcomes; it demonstrated feasibility 
but in an odd twist, even thrombolysis used at this very early phase, did not result in improved 
outcomes  [11] . This finding suggests that time alone may not guarantee a favorable outcome 
and that the time effect is modified by the collateral perfusion status.
 In another study, looking at the late extreme of the thrombolysis window, the European 
Cooperative Acute Stroke Study III (ECASS III) trial extended thrombolysis use to 4.5 h based 
on a very simplistic imaging approach with noncontrast CT scan  [12] . ECASS III was a positive 
study with key results leading to extension of the thrombolysis window to 4.5 h. This positive 
result emerged only because it was largely driven by the patient subgroup between a time 
window of 4 and 4.5 h  [13] . Additionally, the subgroup of patients with an extended throm-
bolysis window of 4–4.5 h did far better than either subgroups of 3–3.5 h or 3.5–4 h, without 
any evidence of a graded relationship with respect to time. A possible explanation to this 
observation is that these latest patients could be recruited with CT findings that still looked 
benign, likely reflecting a sustained collateral status. Ironically, it is exactly those patients 
who one would exclude, due to the restrictive time window alone, yet they benefited the 
most. In sum, patients with better collateral flow may survive longer without extensive 
injury and such robust collateral status not only permits, but enhances the effects of reper-
fusion.
 Baseline Imaging Patterns Predict Response 
 The Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 
(DEFUSE) study revealed that different imaging patterns may identify patient subgroups that 
are likely to benefit from reperfusion  [14] . Recent data have shown that a malignant DWI 
pattern may be seen even in patients who present within 4.5 h, at various stages within the 
standard thrombolysis window  [15, 16] . The DEFUSE study also demonstrated that with 
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perfusion imaging, a substantial percentage of patients have a malignant pattern even within 
the first few hours of symptom onset. Hence, imaging may be important at these very early 
stages to identify and possibly exclude malignant profile cases that are likely to have poor 
flow and poor response to revascularization  [14, 15, 17] .
 Serial Imaging 
 The Alberta Stroke Program Early CT Score (ASPECTS) is a very useful systematic 
approach to grade severity of ischemia on CT/MRI, for monitoring serial changes and to 
evaluate the impact of recanalization and reperfusion  [18–20] .
 Serial noninvasive advanced imaging, such as CT/MRA or perfusion imaging, could be 
used to chronicle recanalization or the change in arterial patency. Such serial perfusion 
imaging may demonstrate reperfusion, yet the same technique must be applied at each time 
point to definitively and accurately document recanalization or reperfusion  [21] . This 
becomes important because one can start to study the parameters mentioned earlier in terms 
of voxel or region-of-interest-based changes in specific regions of the brain. For example, one 
can assess serial time-to-maximum (Tmax) changes from baseline to 24 h to delineate Tmax 
evidence of reperfusion within a given voxel. One can also look individually at how the Tmax 
changes from one value to the next in a single area of the brain, and each of these gives us a 
different definition or dimension of reperfusion  [8] . Such coregistration of serial imaging 
techniques may also map voxel fate with respect to hemorrhagic transformation and ischemic 
infarction. Serial changes on gradient echo sequences can be used to coregister studies at two 
different time points and map hemorrhagic transformation, the degree of hemorrhage, and 
to correlate which voxel or specific area is affected. Ischemic infarct evolution is not only 
about the change in size of lesion growth, or even reversal, but also about predicting the tissue 
fate of which region stays unchanged, which areas suffer severe injury and which have 
improved or reversed ( fig. 3 ).
 Hyperperfusion can also be readily demonstrated on arterial spin-labeled MRI, whereas 
it is difficult to detect with standard dynamic susceptibility contrast techniques. Therefore, 
serial imaging may chronicle the dynamics of territorial perfusion from acute to chronic 
phases after stroke, and it may provide novel insight on dynamics of reperfusion and hemor-
rhagic transformation ( fig. 4 )  [22] .
 Reperfusion 
 Definitive Reperfusion 
 It is possible to measure the amount of reperfusion in downstream tissue using the 
Thrombolysis in Cerebral Infarction (TICI) score on angiography. However, definitive or 
optimal reperfusion needs to be defined based on associated clinical outcomes. Different 
therapies are currently used for achieving reperfusion or revascularization, and the effects of 
these different approaches can be evaluated with serial imaging. Such information may be 
used to define optimal or definitive reperfusion in terms of serial imaging correlation with 
clinical outcome, instead of focusing solely on angiographic success.
 TICI and ASITN/SIR Grading Scales 
 To assess angiographic results, the TICI score published in 2003 has been used, with 
categories of reperfusion ranging from grade 0 to 3; the higher the grade, the more complete 
the antegrade perfusion beyond the occlusive lesion  [23] . The modified TICI was later intro-
duced and used in various studies such as the Interventional Management of Stroke (IMS) III 
trial, and it made a key distinction in the subcategory 2, further defined as grades 2a (<50%) 
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and 2b (>50%)  [24, 25] . This scoring system is still undergoing revision with consensus 
recently established in a pending publication endorsed by numerous societies.
 Collateral grade has mainly been scored with the American Society of Interventional 
and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) col-
lateral flow grading system  [23] . Although it is relatively crude and even suboptimal, it has 
been a practical system to use and an important one that is most widely employed for this 
purpose.
Onset ADC ADC prediction Tmax predictionOnset Tmax Ground truth
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.1 0.2 0.3 0.4 0.5 0.6 0.7
 Fig. 3. Coregistration of serial imaging studies in predicting tissue fate after ischemic infarction. ADC and Tmax 
perfusion at onset are illustrated with the corresponding prediction of the models and for 6 patients. Predic-
tions were compared to the ground truth (red contours; color refers to the online version only) manually out-
lined on follow-up FLAIR at day 4.  
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 Defining Definitive Reperfusion 
 The definition of reperfusion was certainly advanced by DEFUSE-2, where the investi-
gators did not just look at baseline patterns but also patterns of reperfusion. They used target 
mismatch as the main identification for selection of optimal candidates, but there were also 
separate PWI criteria for reperfusion which was greater than a 50% reduction in PWI 
(measured as Tmax greater than 6 s) volume at early follow-up and at final angiography, as 
TICI grades 2b or 3  [15] .
 Different definitions for reperfusion have been used in other studies such as the Throm-
bectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO) 2 
and SOLITAIRE TM FR With the Intention For Thrombectomy (SWIFT) trials, in which successful 
revascularization was defined as TICI grades 2a, 2b or 3 in TREVO 2  [3] and Thrombolysis In 
Myocardial Infarction (TIMI) grades 2 and 3 in all treatable vessels in the SWIFT trial  [2] . In 
these two studies, with respect to the successful rate of revascularization, both met their 
prespecified end point. The outcome measurements, however, were different. The SWIFT 
 Fig. 4. Arterial spin-labeled MRI study 
demonstrating hyperperfusion in the left 
middle cerebral artery territory after re-
perfusion. 
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trial used a novel end point that comprises successful revascularization without symptomatic 
intracranial hemorrhage  [2] . This composite end point was used for the first time to define 
successful reperfusion. Therefore, it is possible to use a combination of angiographic measures 
of revascularization or reperfusion as well as intervening tissue events, suggestive of hemor-
rhage or infarction as it relates to clinical outcome, to refine the definitions used in a trial to 
best approximate definitive reperfusion.
 Definitive reperfusion could be defined based on clinical outcomes, but there is not neces-
sarily an optimal degree of TICI reperfusion that has been identified to date. In addition, the 
optimal threshold for differentiating TICI grade 2b between the two different systems, TICI 
and modified TICI, remains unknown. Although SWIFT used symptomatic intracranial hemor-
rhage as a criterion, it excluded other forms of hemorrhage. It is not known whether other 
forms of hemorrhage may also need to be considered.
 In this context, it is now possible to look at flow from basic pathophysiology to prehos-
pital treatment with neuroprotective agents, from baseline imaging and different combina-
tions of therapy between neuroprotection and revascularization, and also to measure 
precisely what happens not just after revascularization but also during the subsequent 
hospital course. For all these purposes, imaging plays a central role in what may be viewed as 
the future of ischemic stroke to elucidate the importance of flow in treatment of large vessel 
occlusive disorders.
 Intracranial Atherosclerosis 
 Up to now, the discussion of acute ischemic stroke has mainly focused on clots or the 
assumption of thromboembolism; intracranial atherosclerosis (ICAS) is another important 
etiological entity that should not be overlooked. ICAS trials have enrolled patients with recent 
ischemia, illustrating that blood flow patterns may predict outcome in such patients  [26] . 
Akin to prior discussion of acute ischemic stroke, there is a balance or homeostasis of flow 
between limited forward flow as measured by the TICI scale and retrograde collateral flow.
 A single perfusion imaging provides only snapshots of the dynamic process in the brain 
and associated vasculature, unlike serial imaging. However, some novel postprocessing tech-
niques permit evaluation of collateral perfusion patterns. The dynamic nature of cerebral 
blood volume collapse from the core to more peripheral areas at risk may be predicted with 
novel techniques that detect regional variations or gradients. Cerebral blood volume gradients 
within a region or arterial territory of the brain may be depicted on a single static imaging 
study ( fig. 5 )  [27] .
 Fig. 5. Gradient map of cerebral blood 
volume illustrating regional variations in 
this critical perfusion parameter during 
acute stroke because of left middle cere-
bral artery occlusion. The circumscribed 
area of increased gradients around the 
core offers insight on the potential expan-
sion of ischemic injury into the surround-
ing penumbra during the ensuing hours. 
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 Analysis of collaterals in the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) 
study showed that outcome can be strongly and potently predicted based on collateral flow, 
above and beyond the degree or percentage of luminal stenosis  [26] . The importance of 
percent stenosis, previously regarded as one of the most significant factors, to predict subse-
quent events is actually negated once collateral flow data are considered. Interestingly, the 
majority of patients with ICAS that suffer recurrent strokes do not have severe lesions as 
defined by the degree of luminal caliber reduction. The definition of severe may therefore be 
reclassified or redefined based on flow and not merely on the percentage of maximal stenosis.
 In the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in 
Intracranial Stenosis (SAMMPRIS)  [28]  study, it was shown that blood flow was also an 
important factor in predicting outcome or early recurrent stroke in the territory. For early 
recurrent stroke, when there was good collateral flow, in both medical and stenting arms, the 
rate of recurrence was 0%  [29] . This is in accordance with physics dictated by the Hagen-
Poiseuille equation that not just the degree of maximal luminal reduction matters but 
numerous other anatomical features like lesion length, viscosity of blood flow and other 
factors that may be important as they affect the pressure gradient across the lesion.
 All these specific anatomical variables may be difficult to study, yet advanced imaging 
techniques such as computational fluid dynamics (CFD), may provide excellent details about 
hemodynamics and the impact of a stenosis or ICAS lesions  [28, 30] . Another imaging entity 
akin to the fractional flow reserve (FFR) measure that has been used in cardiology  [31] looks 
simply at the flow or the degree of pressure drop across a lesion. Such normalized ratios for 
hemodynamic impact of a given lesion may be used to study mechanisms of arteriogenesis 
and shear stress in more detailed fashion. FFR was performed originally with maximal vaso-
dilatation by using adenosine  [32] . Recently, the approaches have moved away from use of a 
hemodynamic reserve challenge to noninvasive methods  [33] . A novel technique converts 
digital subtraction angiography from 2D to 3D to create a geometrical mesh that allows for 
manipulation of the geometry and CFD calculations  [34] . The pressure gradient from upstream 
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 Fig. 6. CFD model depicting the 
high (yellow; color refers to the 
online version only) wall shear 
stress at the left middle cerebral 
artery stenosis. 
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